Cetera Advisors LLC Has $24.77 Million Position in Johnson & Johnson (NYSE:JNJ)

Cetera Advisors LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 149,625 shares of the company’s stock after acquiring an additional 3,682 shares during the quarter. Cetera Advisors LLC’s holdings in Johnson & Johnson were worth $24,766,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Atlantic Private Wealth LLC acquired a new stake in shares of Johnson & Johnson in the first quarter valued at $32,000. 25 LLC acquired a new stake in shares of Johnson & Johnson in the first quarter valued at $55,000. Horizons Wealth Management increased its stake in shares of Johnson & Johnson by 1,730.0% in the second quarter. Horizons Wealth Management now owns 366 shares of the company’s stock valued at $61,000 after buying an additional 346 shares in the last quarter. Bay Harbor Wealth Management LLC bought a new position in Johnson & Johnson in the second quarter valued at about $66,000. Finally, Mcmillion Capital Management Inc. bought a new position in Johnson & Johnson in the second quarter valued at about $103,000. 68.40% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on JNJ shares. Barclays raised their price target on Johnson & Johnson from $158.00 to $162.00 and gave the company an “equal weight” rating in a report on Thursday, October 12th. Raymond James decreased their price target on Johnson & Johnson from $179.00 to $172.00 and set an “outperform” rating on the stock in a report on Wednesday, October 18th. Wells Fargo & Company reduced their target price on Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating on the stock in a report on Thursday, August 31st. Royal Bank of Canada started coverage on Johnson & Johnson in a report on Wednesday, October 4th. They set an “outperform” rating and a $178.00 target price on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Friday. Eight equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $169.19.

Johnson & Johnson Price Performance

Shares of JNJ opened at $149.91 on Tuesday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.96 and a current ratio of 1.21. The stock has a 50 day simple moving average of $154.52 and a 200 day simple moving average of $160.29. Johnson & Johnson has a 52-week low of $144.95 and a 52-week high of $181.04. The firm has a market capitalization of $360.88 billion, a PE ratio of 11.13, a P/E/G ratio of 3.00 and a beta of 0.58.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 17th. The company reported $2.66 EPS for the quarter, beating the consensus estimate of $2.52 by $0.14. The firm had revenue of $21.35 billion for the quarter, compared to analysts’ expectations of $21 billion. Johnson & Johnson had a return on equity of 37.14% and a net margin of 36.32%. Sell-side analysts predict that Johnson & Johnson will post 10.1 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 5th. Shareholders of record on Tuesday, November 21st will be paid a $1.19 dividend. This represents a $4.76 annualized dividend and a yield of 3.18%. The ex-dividend date is Monday, November 20th. Johnson & Johnson’s payout ratio is 35.34%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.